These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35100462)

  • 1. An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care.
    Gracen L; Hayward KL; Aikebuse M; Williams S; Russell A; O'Beirne J; Powell EE; Valery PC
    Diabet Med; 2022 Jun; 39(6):e14799. PubMed ID: 35100462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.
    Gracen L; Hayward KL; Aikebuse M; Russell A; O'Beirne J; McPhail S; Irvine KM; Williams S; Valery PC; Powell EE
    BMC Health Serv Res; 2022 Apr; 22(1):487. PubMed ID: 35413987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
    Kanwal F; Shubrook JH; Adams LA; Pfotenhauer K; Wai-Sun Wong V; Wright E; Abdelmalek MF; Harrison SA; Loomba R; Mantzoros CS; Bugianesi E; Eckel RH; Kaplan LM; El-Serag HB; Cusi K
    Gastroenterology; 2021 Nov; 161(5):1657-1669. PubMed ID: 34602251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations.
    Arrese M; Barrera F; Triantafilo N; Arab JP
    Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):849-866. PubMed ID: 31353974
    [No Abstract]   [Full Text] [Related]  

  • 7. Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study.
    Hallsworth K; Dombrowski SU; McPherson S; Anstee QM; Avery L
    Transl Behav Med; 2020 Oct; 10(4):1016-1030. PubMed ID: 31120519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102446. PubMed ID: 35259705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey.
    Islam KB; Brandman D; Chu JN; Goldman ML; Fox RK
    Dig Dis Sci; 2023 Feb; 68(2):434-438. PubMed ID: 36178567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
    Khneizer G; Rizvi S; Gawrieh S
    Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
    Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
    World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
    Marjot T; Sbardella E; Moolla A; Hazlehurst JM; Tan GD; Ainsworth M; Cobbold JFL; Tomlinson JW
    Diabet Med; 2018 Jan; 35(1):89-98. PubMed ID: 29094442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.
    Johnson AL; Hayward KL; Patel P; Horsfall LU; Cheah AEZ; Irvine KM; Russell AW; Stuart KA; Williams S; Hartel G; Valery PC; Powell EE
    Hepatol Commun; 2022 Apr; 6(4):728-739. PubMed ID: 34783191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver.
    Godinez-Leiva E; Bril F
    Curr Hypertens Rev; 2021; 17(2):94-111. PubMed ID: 33302841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.
    Virović Jukić L; Grgurević I; Mikolašević I; Filipec Kanižaj T; Milić S; Mrzljak A; Premužić M; Hrstić I; Knežević-Štromar I; Ljubičić N; Ostojić R; Stojsavljević Shapeski S; Amerl-Šakić V; Marković NB; Rađa M; Soldo D; Sobočan N; Lalovac M; Puljiz Ž; Podrug K; Ladić D
    Acta Clin Croat; 2021 Dec; 60(Suppl 2):36-52. PubMed ID: 35528151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers and enabling factors in weight management of patients with nonalcoholic fatty liver disease: A qualitative study using the COM-B model of behaviour.
    Gu Y; Zhou R; Kong T; Zhang W; Chen Y; Wang C; Shi J; Hu Y
    Health Expect; 2023 Feb; 26(1):355-365. PubMed ID: 36385729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
    Cusi K; Isaacs S; Barb D; Basu R; Caprio S; Garvey WT; Kashyap S; Mechanick JI; Mouzaki M; Nadolsky K; Rinella ME; Vos MB; Younossi Z
    Endocr Pract; 2022 May; 28(5):528-562. PubMed ID: 35569886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.